Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS)

Group 1 - Keros Therapeutics, Inc. (NASDAQ: KROS) shares are trading at a small discount to cash after the company abandoned its cibotercept program, leaving it with one wholly owned asset [2] - The company has faced challenges in 2025, impacting its overall performance and strategic direction [2] Group 2 - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions on trade ideas and weekly market commentary [2]